Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias

This phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…